Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246240131> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2246240131 abstract "e16096 Background: Renal medullary carcinoma (RMC) is an epithelial malignant tumor arising from collecting duct epithelium. The tumor is almost exclusive to young black patients with the sickle cell hemoglobinopathies, primarily sickle cell trait. This is a rare and highly aggressive tumor that is shown to be most resistant to chemotherapy. In an effort to evaluate treatment outcomes, we retrospectively examined those patients diagnosed with RMC who were treated with and without bevacizumab based regimens. Methods: We reviewed the genitourinary medical oncology database at M. D. Anderson Cancer Center for patient diagnosed between 1999–2008 with histology proven RMC. Vital statistics of birth and death dates were noted. In addition, detailed chemotherapy regimen as well as medical and radiological data were also obtained. Results: All patients had metastatic disease (stage IV) to at least one distant site at presentation. Distant sites included bone, liver or lungs. A sample of five black males 5/9 (53%) were treated with therapy that included a 2 or 3 drug combinations of Adriamycin, Taxol, Gemzar, cisplatin, or Gleevac. Median survival was 12.7 months (3.2–22.2) while median age was 31 year (28–59). Only 4/9 (47%) patients received bevacizumab based therapy in a 2 or 3 drug combinations with Gemzar, Xeloda, cisplatin, or Taxol. In this group, 50% were females, median age of 36 years (33–39) and median survival of 18.5 months (15.5–22.8). Conclusions: Sickle cell trait was confirmed for all in this group diagnosed with RMC. 8/9 of these patients were black and 1/9 South-Asian. The group that received bevacizumab based therapy had a median survival of 5.8 months longer. Future studies, including genetic studies on the tumor types are essential to determining the SNP profiles of renal cell carcinoma in black patients. Furthermore, a prospective multicenter trial should be developed to evaluate the efficacy of bevacizumab based regimens in renal medullary carcinoma in this population. No significant financial relationships to disclose." @default.
- W2246240131 created "2016-06-24" @default.
- W2246240131 creator A5007689146 @default.
- W2246240131 creator A5028293909 @default.
- W2246240131 creator A5038855385 @default.
- W2246240131 creator A5049570174 @default.
- W2246240131 creator A5062038822 @default.
- W2246240131 date "2009-05-20" @default.
- W2246240131 modified "2023-09-25" @default.
- W2246240131 title "Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma" @default.
- W2246240131 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e16096" @default.
- W2246240131 hasPublicationYear "2009" @default.
- W2246240131 type Work @default.
- W2246240131 sameAs 2246240131 @default.
- W2246240131 citedByCount "3" @default.
- W2246240131 countsByYear W22462401312015 @default.
- W2246240131 countsByYear W22462401312018 @default.
- W2246240131 countsByYear W22462401312019 @default.
- W2246240131 crossrefType "journal-article" @default.
- W2246240131 hasAuthorship W2246240131A5007689146 @default.
- W2246240131 hasAuthorship W2246240131A5028293909 @default.
- W2246240131 hasAuthorship W2246240131A5038855385 @default.
- W2246240131 hasAuthorship W2246240131A5049570174 @default.
- W2246240131 hasAuthorship W2246240131A5062038822 @default.
- W2246240131 hasConcept C126322002 @default.
- W2246240131 hasConcept C133507102 @default.
- W2246240131 hasConcept C141071460 @default.
- W2246240131 hasConcept C143998085 @default.
- W2246240131 hasConcept C2776694085 @default.
- W2246240131 hasConcept C2777566322 @default.
- W2246240131 hasConcept C2777802072 @default.
- W2246240131 hasConcept C2779134260 @default.
- W2246240131 hasConcept C71924100 @default.
- W2246240131 hasConceptScore W2246240131C126322002 @default.
- W2246240131 hasConceptScore W2246240131C133507102 @default.
- W2246240131 hasConceptScore W2246240131C141071460 @default.
- W2246240131 hasConceptScore W2246240131C143998085 @default.
- W2246240131 hasConceptScore W2246240131C2776694085 @default.
- W2246240131 hasConceptScore W2246240131C2777566322 @default.
- W2246240131 hasConceptScore W2246240131C2777802072 @default.
- W2246240131 hasConceptScore W2246240131C2779134260 @default.
- W2246240131 hasConceptScore W2246240131C71924100 @default.
- W2246240131 hasLocation W22462401311 @default.
- W2246240131 hasOpenAccess W2246240131 @default.
- W2246240131 hasPrimaryLocation W22462401311 @default.
- W2246240131 hasRelatedWork W1603389188 @default.
- W2246240131 hasRelatedWork W1970157608 @default.
- W2246240131 hasRelatedWork W2006784804 @default.
- W2246240131 hasRelatedWork W2033093542 @default.
- W2246240131 hasRelatedWork W2093370795 @default.
- W2246240131 hasRelatedWork W2104602867 @default.
- W2246240131 hasRelatedWork W2126021534 @default.
- W2246240131 hasRelatedWork W2244361054 @default.
- W2246240131 hasRelatedWork W2299408353 @default.
- W2246240131 hasRelatedWork W2345404243 @default.
- W2246240131 hasRelatedWork W2411130734 @default.
- W2246240131 hasRelatedWork W2472347302 @default.
- W2246240131 hasRelatedWork W2515974529 @default.
- W2246240131 hasRelatedWork W2739048966 @default.
- W2246240131 hasRelatedWork W2756034090 @default.
- W2246240131 hasRelatedWork W2887328516 @default.
- W2246240131 hasRelatedWork W2910484869 @default.
- W2246240131 hasRelatedWork W2979693590 @default.
- W2246240131 hasRelatedWork W3153072275 @default.
- W2246240131 hasRelatedWork W2050215976 @default.
- W2246240131 isParatext "false" @default.
- W2246240131 isRetracted "false" @default.
- W2246240131 magId "2246240131" @default.
- W2246240131 workType "article" @default.